Search “muse cells vs stem cells” and you’ll notice a small mismatch buried in the question itself. These aren’t two competing categories fighting for the same territory – MUSE cells live inside the mesenchymal stem cell population, not alongside it. Ask what actually separates them, and the real answer is about a specific subtype nested within a much larger, more familiar group: mesenchymal stem cells (MSCs).
Strip away the jargon and the short version reads like this: MUSE cells are a naturally occurring subset identified within MSC populations pulled from bone marrow, fat tissue, and other sources in the body. Unique surface markers and an unusual tolerance for cellular stress set this subgroup apart from its neighbors. Below: how general stem cells and MSCs work, where MUSE cells diverge from that baseline, what the research shows, and where the safety picture stands today.
What Are Stem Cells (and Mesenchymal Stem Cells)?
Every stem cell, regardless of type, shares two core capabilities: it can copy itself indefinitely (self-renewal), and it can turn into other, more specialized cell types (differentiation). Where cell types part ways is in how far that differentiation can go. Embryonic stem cells sit at the far end of the spectrum – pluripotent, capable of becoming nearly any cell in the body. Adult, or somatic, stem cells work with a narrower playbook; they’re usually described as multipotent, restricted to a smaller set of outcomes, yet still central to how tissue gets maintained and repaired across a lifespan.
Mesenchymal stem cells (MSCs) sit near the center of regenerative medicine research – no adult stem cell type has been studied more. Bone marrow and adipose (fat) tissue are the two most common sources, though umbilical cord tissue and dental pulp also yield usable populations. MSCs differentiate along a fairly fixed set of pathways – osteogenic (bone), chondrogenic (cartilage), and adipogenic (fat) lineages – and carry immunomodulatory properties that may help shape local inflammatory activity. Well over a thousand peer-reviewed studies now back this cell type, making it the most established name in the field by a wide margin. Curious how MSCs stack up against another well-researched adult stem cell type? Our article on mesenchymal stem cells vs. hematopoietic stem cells breaks down where their roles diverge.
What Are MUSE Cells?
Rewind to 2010: a research team led by Dr. Mari Dezawa noticed something odd happening in cell cultures pushed to their breaking point. A small fraction of cells kept surviving conditions – extended trypsin exposure, serum starvation, low-oxygen environments – that reliably killed off everything else in the dish. That survival instinct is the reason these cells carry the name MUSE: Multilineage-differentiating Stress-Enduring cells (Kuroda et al., Proceedings of the National Academy of Sciences, 2011). What looked at first like a curious footnote turned out to be a clue pointing toward something deeper about how these cells function.
The marker that sets MUSE cells apart from ordinary MSCs is SSEA-3 (stage-specific embryonic antigen 3), a glycosphingolipid researchers use to sort and isolate them from the larger mesenchymal stromal pool, typically alongside standard mesenchymal markers such as CD105 (Que et al., Frontiers in Cell and Developmental Biology, 2024). SSEA-3 doesn’t just sit on the cell surface as a convenient tag, either – evidence points to it playing an active role, in tandem with FGF2 signaling, in preserving MUSE cell stemness and steering lineage commitment (Aprile et al., Cell Proliferation, 2022).
What draws the most scientific attention, though, is spontaneous multilineage differentiation. MUSE cells appear able to give rise to cell types spanning all three embryonic germ layers – ectoderm, mesoderm, and endoderm – without any genetic reprogramming or artificial induction, and current evidence suggests this happens without triggering teratomas, the tumors sometimes linked to more aggressively reprogrammed pluripotent cell types (Alanazi et al., Cells, 2023). These cells are endogenous – they occur naturally in the body rather than being engineered in a lab – and make up only a small fraction of the total MSC population found in bone marrow, adipose tissue, and peripheral blood.
MUSE Cells vs Stem Cells: Key Differences in Biology and Research
Line up MUSE cells vs mesenchymal stem cells side by side, and a handful of concrete distinctions emerge.
Differentiation potential. Standard MSCs stay within a fairly narrow lane – bone, cartilage, and fat lineages, typically. MUSE cells, by contrast, appear to differentiate spontaneously across all three germ layers without requiring any genetic manipulation – a capability more often associated with pluripotent cell types than with ordinary adult stem cells (Alanazi et al., 2023).
Identification and isolation. Researchers sort standard MSCs using markers like CD105, CD90, and CD73. Muse stem cells vs MSC identification hinges on one additional marker: SSEA-3. MUSE cells test positive for it; the rest of the mesenchymal population does not (Que et al., 2024).
Stress tolerance. Surviving the harsh lab conditions that wiped out other cells is literally how MUSE cells got discovered in the first place. That kind of resilience isn’t a defining trait of general MSCs.
Tissue-homing behavior. Some early research suggests MUSE cells pick up on damage signals like sphingosine-1-phosphate (S1P) and migrate toward injured tissue with a degree of specificity, whereas general MSCs delivered intravenously tend to get caught in capillary beds – the lungs, especially (Dezawa, Biogerontology, 2025). Treat this as a promising lead rather than settled science.
Research and clinical development stage. Here’s the difference that matters most for anyone weighing the two in practical terms. MSCs carry decades of research behind them, with well over a thousand published studies and a deep bench of clinical trial data spanning many conditions. MUSE cell research is still young by comparison – real, but early – with a much thinner body of published clinical work and far fewer completed trials to draw on.
The Evidence: What Research Shows
MSC research and MUSE cell research sit at very different points on the maturity timeline.
The MSC evidence base spans orthopedic use cases through immune-related conditions, backed by a large and expanding set of clinical trial data that shapes how researchers approach dosing, delivery, and safety monitoring. That depth is why MSCs remain the default reference point in most regenerative medicine conversations.
MUSE cell research covers less ground numerically, but what exists is methodologically compelling. A comprehensive review characterizes MUSE cells as exhibiting anti-inflammatory, anti-apoptotic, and immunomodulatory activity in preclinical tissue-damage models – without the tumor-formation risk sometimes tied to more heavily reprogrammed pluripotent cell types (Que et al., 2024). A wider survey of the MUSE cell literature points to growing interest across cardiac, neurological, and dermatological research contexts, framing the field as an emerging chapter of stem cell investigation rather than an established treatment category (Alanazi et al., 2023). One direct comparative analysis goes a step further, suggesting purified MUSE cell preparations may behave differently in preclinical models than mixed MSC preparations containing a comparable proportion of MUSE cells – an early but intriguing hint that the non-MUSE cells surrounding them within an MSC population might shape how MUSE cells behave (Dezawa, 2025).
Put together, this evidence points to MUSE cells as a scientifically distinct, actively researched stem cell subtype – just one that sits earlier on the research and clinical development curve than the extensively studied MSC field. Neither observation should be read as a claim that either cell type cures or reverses any specific condition; both remain areas of ongoing, evolving research.
Safety Considerations and Current Status
Before going further, here’s where things stand from a regulatory standpoint.
No MUSE cell-based therapy currently holds FDA approval in the United States for any indication. The field remains emerging, with most available evidence drawn from preclinical work and early-phase trials rather than large, confirmatory studies. General MSC-based approaches have a longer track record, but that history doesn’t translate to broad approval – most MSC applications used in wellness settings are also not FDA-approved for the specific conditions under study and should be treated as investigational.
Individual factors – health history, the condition in question, and exactly how a given protocol is sourced and administered – all shape what might be appropriate for any one person considering a regenerative or cell-based approach. Talk to a qualified healthcare provider who can walk through the current evidence, set realistic expectations, and flag relevant risks before any decision gets made.
Frequently Asked Questions
Are MUSE cells a type of stem cell?
Yes – MUSE cells are a naturally occurring subpopulation of stem cells nested within mesenchymal stem cell populations in bone marrow, adipose tissue, and elsewhere. When people compare muse cells vs stem cells, they’re really asking how this particular subtype differs from the broader stem cell population it belongs to, not comparing two unrelated categories.
What is the main difference between MUSE cells and mesenchymal stem cells?
The sharpest distinction in muse cells vs mesenchymal stem cells comes down to differentiation range and identification method. MUSE cells appear capable of spontaneous multilineage differentiation across all three germ layers and get identified via the SSEA-3 marker, while general MSCs are multipotent and identified using markers such as CD105 and CD90.
How are MUSE cells identified in a lab setting?
The SSEA-3 marker – a glycosphingolipid – is the primary tool researchers use to sort MUSE cells out from a broader mesenchymal stromal cell population. Because MUSE cells also carry standard mesenchymal markers, SSEA-3 positivity currently serves as the defining line in muse stem cells vs MSC identification.
Where are MUSE cells found in the body?
MUSE cells occur naturally as a small slice of the mesenchymal stem cell population in tissues like bone marrow, adipose tissue, and peripheral blood. Nobody manufactures them in a lab – they’re isolated directly from existing tissue sources.
Is MUSE cell therapy FDA-approved?
No. As of this writing, no MUSE cell-based therapy holds FDA approval in the United States for any indication. The field remains part of an active, emerging area of stem cell research and is best discussed with a qualified provider rather than treated as an established therapy option.
Why are MUSE cells considered stress-tolerant?
Because that’s literally how they were found: MUSE cells survived brutal laboratory stress conditions – prolonged enzyme exposure, serum deprivation, low-oxygen environments – that eliminated most other cells in the same culture. That resilience is baked into their name and continues to draw research interest.
Do MUSE cells form tumors like some pluripotent stem cells?
Current research suggests they don’t appear to form teratomas, the type of tumor sometimes associated with highly reprogrammed pluripotent cell types like induced pluripotent stem cells. Researchers consider this one of the more notable safety-relevant characteristics of MUSE cells, though continued study is still warranted.
Which has more research behind it, MUSE cells or general MSCs?
General mesenchymal stem cells, by a wide margin – well over a thousand published studies and years of accumulated clinical trial data back them. MUSE cell research is smaller in scale and earlier in its development timeline, though the body of work has grown meaningfully in recent years.
Key Takeaways
- Muse cells vs stem cells isn’t a comparison between two separate categories – it’s a look at how a rare, specific subtype relates to the broader mesenchymal stem cell population it lives inside.
- Dr. Mari Dezawa’s research team discovered MUSE cells in 2010 after noticing their unusual capacity to survive severe cellular stress.
- SSEA-3 remains the primary marker researchers rely on to separate MUSE cells from the rest of a mesenchymal stromal cell population.
- MUSE cells appear capable of spontaneous multilineage differentiation spanning all three germ layers, while general MSCs stay largely confined to bone, cartilage, and fat lineages.
- Some evidence suggests MUSE cells may home preferentially to damaged tissue, while general MSCs delivered intravenously are more often trapped in capillary beds.
- General MSC research is far more extensive and mature than MUSE cell research, which remains an earlier-stage, rapidly growing field.
- Neither general MSC nor MUSE cell-based therapy currently holds FDA approval for use outside research and early clinical trial settings.
- Anyone exploring stem cell or MUSE cell-related options should do so with guidance from a qualified healthcare provider.
Want to understand how regenerative approaches built around mesenchymal stem cells are used in real-world practice? Visit our stem cell therapy page, or schedule a consultation with the Ways2Well team to talk through what a personalized evaluation could look like. For a deeper dive into the broader claims and evidence surrounding this specific cell type, check out our related article on MUSE stem cells.
References
- Kuroda Y, Kitada M, Wakao S, Nishikawa K, Tanimura Y, Makinoshima H, Goda M, Akashi H, Inutsuka A, Niwa A, Shigemoto T, Nabeshima Y, Nakahata T, Nabeshima Y, Fujiyoshi Y, Dezawa M. “Multilineage-differentiating stress-enduring (Muse) cells are a primary source of induced pluripotent stem cells in human fibroblasts.” Proceedings of the National Academy of Sciences, 2011;108(24):9875-9880. DOI: https://doi.org/10.1073/pnas.1100816108
- Que H, Mai E, Hu Y, Li H, Zheng W, Jiang Y, Han F, Li X, Gong P, Gu J. “Multilineage-differentiating stress-enduring cells: a powerful tool for tissue damage repair.” Frontiers in Cell and Developmental Biology, 2024;12:1380785. DOI: https://doi.org/10.3389/fcell.2024.1380785
- Alanazi RF, Alhwity BS, Almahlawi RM, Alatawi BD, Albalawi SA, Albalawi RA, Albalawi AA, Abdel-Maksoud MS, Elsherbiny N. “Multilineage Differentiating Stress Enduring (Muse) Cells: A New Era of Stem Cell-Based Therapy.” Cells, 2023;12(13):1676. DOI: https://doi.org/10.3390/cells12131676
- Aprile D, Alessio N, Squillaro T, Di Bernardo G, Peluso G, Galderisi U. “Role of glycosphingolipid SSEA-3 and FGF2 in the stemness and lineage commitment of multilineage differentiating stress enduring (MUSE) cells.” Cell Proliferation, 2022;56(1):e13345. DOI: https://doi.org/10.1111/cpr.13345
- Dezawa M. “Comparison of MSCs and Muse cells: the possible use for healthspan optimization.” Biogerontology, 2025;26(4):139. DOI: https://doi.org/10.1007/s10522-025-10275-2
Author: Ways2Well Editorial Team
Reviewed by: Scientific Advisory Board member